Xiao F, Xiao W, Li X, Li R, Zhao K. Cost-effectiveness analysis of Trastuzumab Deruxtecan as second-line treatment for HER2- positive advanced breast cancer. Health Decision [Internet]. 2024 Jul. 12 [cited 2025 May 2];2(S1). Available from: https://www.hksmp.com/journals/hd/article/view/655